Get the Stockscreener App
0.388
0.51%
-0.002
Harvard Bioscience Inc stock is traded at $0.388, with a volume of 289.11K.
It is down -0.51% in the last 24 hours and down -44.18% over the past month.
Harvard Bioscience Inc is a developer, manufacturer, and seller of technologies, specialized products and services that enable fundamental research, discovery, and pre-clinical testing for drug development. Its primary focus is scientific instruments used to advance life sciences and research. With operations in North America, Europe and china it sells through a combination of direct and distribution channels to customers around the world. The product brands of the company include Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs, Multichannel Systems MCS GmbH, and Panlab.. The majority of its revenue comes from the United States.
See More
Previous Close:
$0.39
Open:
$0.38
24h Volume:
289.11K
Relative Volume:
0.92
Market Cap:
$17.44M
Revenue:
$106.79M
Net Income/Loss:
$-8.73M
P/E Ratio:
-1.94
EPS:
-0.2
Net Cash Flow:
$10.81M
1W Performance:
+0.60%
1M Performance:
-44.18%
6M Performance:
-83.77%
1Y Performance:
-90.51%
1-Day Range:
$0.38
$0.415
1-Week Range:
$0.376
$0.4537
52-Week Range:
$0.355
$4.31
Harvard Bioscience Inc Stock (HBIO) Company Profile
Name
Harvard Bioscience Inc
Sector
Industry
Phone
(508) 893-8999
Address
84 OCTOBER HILL RD, HOLLISTON, MA
Compare HBIO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HBIO
Harvard Bioscience Inc
|
0.388 | 17.44M | 106.79M | -8.73M | 10.81M | -0.20 |
|
ISRG
Intuitive Surgical Inc
|
482.74 | 175.60B | 8.35B | 2.32B | 1.30B | 6.41 |
|
BDX
Becton Dickinson Co
|
198.71 | 59.07B | 20.64B | 1.73B | 2.94B | 6.02 |
|
ALC
Alcon Inc
|
92.54 | 44.80B | 9.91B | 1.02B | 665.00M | 2.05 |
|
RMD
Resmed Inc
|
212.91 | 31.51B | 4.93B | 1.25B | 1.38B | 8.47 |
|
COO
The Cooper Companies, Inc.
|
79.51 | 15.75B | 3.90B | 392.30M | 288.10M | 1.95 |
Harvard Bioscience Inc Stock (HBIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-09-25 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| Mar-10-23 | Upgrade | The Benchmark Company | Speculative Buy → Buy |
| Jan-07-21 | Upgrade | The Benchmark Company | Speculative Buy → Buy |
| Dec-09-20 | Initiated | Northland Capital | Outperform |
| Nov-10-20 | Initiated | KeyBanc Capital Markets | Overweight |
| Jul-08-19 | Downgrade | Janney | Buy → Neutral |
| Jan-24-18 | Reiterated | Janney | Buy |
| Jan-23-18 | Reiterated | The Benchmark Company | Buy |
| Nov-17-16 | Initiated | Singular Research | Buy |
| Jul-28-15 | Initiated | The Benchmark Company | Buy |
View All
Harvard Bioscience Inc Stock (HBIO) Latest News
Harvard Bioscience’s Bertrand Loy to Step Down - TipRanks
Benchmark reiterates Harvard Bioscience stock with $4.50 target By Investing.com - Investing.com India
Harvard Bioscience’s (HBIO) Sector Weight Rating Reiterated at KeyCorp - Defense World
Harvard Bioscience (HBIO) Announces CFO Transition - GuruFocus
Harvard Bioscience Announces CFO Transition | HBIO Stock News - GuruFocus
Harvard Bioscience (HBIO) Sees CFO Transition with Interim Appoi - GuruFocus
Lacklustre Performance Is Driving Harvard Bioscience, Inc.'s (NASDAQ:HBIO) 49% Price Drop - simplywall.st
Harvard Bioscience Appoints Mark Frost as Interim CFO - citybiz
Harvard Bioscience appoints interim CFO amid market challenges By Investing.com - Investing.com Canada
Harvard Bioscience CFO Jennifer Cote Resigns - marketscreener.com
Harvard Bioscience CFO Resignation and Interim Appointment - TipRanks
Harvard Bioscience appoints interim CFO amid market challenges - Investing.com
Harvard Bioscience Announces CFO Transition - The Manila Times
KeyBanc cuts Harvard Bioscience stock rating on financing risk By Investing.com - Investing.com Canada
Estimating The Fair Value Of Harvard Bioscience, Inc. (NASDAQ:HBIO) - Yahoo Finance
KeyBanc Downgrades Harvard Bioscience to Sector Weight From Overweight, Removes $3 Price Target - marketscreener.com
KeyBanc cuts Harvard Bioscience stock rating on financing risk - Investing.com
Harvard Bioscience Slides As Insider Purchases Lose Another US$76k - simplywall.st
Harvard Bioscience (NASDAQ:HBIO) Price Target Cut to $4.50 by Analysts at Benchmark - Defense World
Harvard Bioscience at 37th Annual ROTH Conference: Strategic Growth Amid Challenges By Investing.com - Investing.com South Africa
Harvard Bioscience at 37th Annual ROTH Conference: Strategic Growth Amid Challenges - Investing.com
Harvard Bioscience, Inc. (NASDAQ:HBIO) Q4 2024 Earnings Call Transcript - Insider Monkey
Harvard Bioscience Full Year 2024 Earnings: EPS Beats Expectations - Yahoo Finance
Harvard Bioscience Inc (HBIO) Q4 2024 Earnings Call Highlights: - GuruFocus.com
Harvard Bioscience Inc (HBIO) Q4 2024 Earnings Call Highlights: Navigating Challenges with ... By GuruFocus - Investing.com Canada
Harvard Bioscience Reports 2024 Financial Results - TipRanks
Harvard Bioscience Navigates Growth Amid Challenges - TipRanks
Harvard Bioscience secures waiver for credit covenant By Investing.com - Investing.com Australia
Harvard Bioscience, Inc. to Participate in Two Investor Conferences in March 2025 - GlobeNewswire
Harvard Bioscience CEO to Host Fireside Chats at Roth and KeyBanc Healthcare Forums - StockTitan
Harvard Bioscience Announces Fourth Quarter and Full-Year 2024 Financial Results - GlobeNewswire
Earnings call transcript: Harvard Bioscience Q4 2024 beats expectations but faces market challenges - Investing.com
Harvard Bioscience Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Harvard Bioscience slumps after weak revenue forecast - TradingView
HARVARD BIOSCIENCE Earnings Results: $HBIO Reports Quarterly Earnings - Nasdaq
Harvard Bioscience reports Q4 adjusted EPS 6c vs. 4c last year - TipRanks
Harvard Bioscience earnings beat, revenue topped estimates By Investing.com - Investing.com UK
Harvard Bioscience Achieves Profit Turnaround Despite Revenue Challenges in Latest Quarter - StockTitan
Harvard Bioscience IncQ4 2024 Revenues $24.6 Million -March 12, 2025 at 07:04 am EDT - Marketscreener.com
Harvard Bioscience Q4 and Full-Year 2024 Financial Results - TradingView
Harvard Bioscience secures waiver for credit covenant - Investing.com
Harvard BioscienceExploring Alternative Capital Sources For Refinancing Outstanding Indebtedness By June 30 - Marketscreener.com
Costco Price Plunge Equals Opportunity for Investors - The Globe and Mail
Harvard Bioscience (HBIO) Expected to Announce Earnings on Wednesday - The AM Reporter
Harvard Bioscience, Inc. to Host Earnings Call - ACCESS Newswire
HBIO stock touches 52-week low at $0.86 amid market challenges - Investing.com Australia
Harvard Bioscience Inc Stock (HBIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.90%
3.46%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):